Informed consent is poorly documented when obtaining toxicology testing at delivery in a Massachusetts cohort

• Published in: American journal of obstetrics & gynecology MFM 2022-07, Vol.4 (4), p.100621-100621, Article 100621
• Main Authors: Koenigs, Kathleen J., Chou, Joseph H., Cohen, Samuel, Nolan, Moira, Liu, Gina, Terplan, Mishka, Cummings, Brian M., Nielsen, Timothy, Smith, Nicole A., Distefano, Joseph, Bernstein, Sarah N., Schiff, Davida M.
• Format: Article
• Language: English
• Subjects: addiction medicine; Child; child protective services; Cohort Studies; Female; hospital policy; Humans; Infant, Newborn; Informed Consent; mandated reporting; medical ethics; Obstetric Labor, Premature; Odds Ratio; patient consent; peripartum period; Retrospective Studies; substance use disorders; toxicology testing
• ISSN: 2589-9333; 2589-9333
• DOI: 10.1016/j.ajogmf.2022.100621

Positive toxicology testing at delivery can have enormous consequences for birthing persons and their families, including charges of child abuse or neglect and potential loss of custody for the birthing parent. Therefore state and national guidelines stipulate that, clinicians must obtain consent before toxicology testing at delivery. This study aimed (1) to determine clinician documentation of patient consent for peripartum toxicology testing and (2) to characterize the extent to which patient and hospital characteristics were associated with documented consent. This was a retrospective cohort of individuals who underwent toxicology testing within 96 hours of delivery between April 2016 and April 2020 at 5 affiliated hospitals across Massachusetts. Medical records were reviewed for documentation of clinician intent to obtain maternal toxicology, testing indication, verbal consent to testing, and child protective services involvement. Hierarchical multivariable logistic regression was used to examine the association between patient and hospital characteristics and documentation of verbal consent. Among 60,718 deliveries, 1562 maternal toxicology tests were obtained. Verbal consent for testing was documented in 466 cases (29.8%). Documented consent was lacking across most demographic groups. Consent was no more likely to be documented when a report was filed with child protective services and less likely in cases where the birthing parent lost custody before discharge (P=.003). In our multivariable model, consent was least likely to be documented when a maternal complication (abruption, hypertension, preterm labor, preterm premature rupture of membranes, or intrauterine fetal demise) was the indication for testing (adjusted odds ratio, 0.46; 95% confidence interval, 0.28–0.76). Verbal consent was twice as likely to be documented in delivery hospitals with established consent policies (adjusted odds ratio, 2.10; 95% confidence interval, 1.01–4.37). Consent for toxicology testing at delivery seemed to be infrequently obtained on the basis of clinician documentation. Provider education and hospital policies for obtaining informed consent are needed to protect the rights of birthing individuals.